FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.ebm
Resource TypeEvidence
IdEvidence-236978.json
FHIR VersionR6

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: Evidence 236978

version: 70; Last updated: 2025-10-07 17:12:54+0000; Language: en

Profile: ComparativeEvidence

url: https://fevir.net/resources/Evidence/236978

identifier: FEvIR Object Identifier/236978, outcomeId/313964, picoId/85798, sectionId/73215

name: Genital_infection_from_MAGICapp_313964

title: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

citeAs:

MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236978. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236978. Computable resource at: https://fevir.net/resources/Evidence/236978#json.

status: Active

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication)ComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

RelatesTos

-TypeTarget[x]
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

assertion:

SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.

variableDefinition

description:

Adults with type 2 diabetes

variableRole: Population

observed: Adults with type 2 diabetes and CVD and CKD

variableDefinition

description:

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableRole: Exposure

comparatorCategory: GLP-1 RA

observed: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableDefinition

description:

Genital infection

variableRole: Outcome

observed: Genital infection

synthesisType: SYSTEMATIC_REVIEW

studyDesign: randomized assignment

statistic

description:

Risk Difference 15.8% (CI95 6.4% to 29.9%)

statisticType: risk difference

quantity: 0.158

SampleSizes

-NumberOfStudiesNumberOfParticipants
*21282

AttributeEstimates

-TypeRange
*CI950.064-0.299

statistic

description:

OR 5.0 (CI95 2.45 to 10.2)

statisticType: odds ratio

quantity: 5

SampleSizes

-NumberOfStudiesNumberOfParticipants
*21282

AttributeEstimates

-TypeRange
*CI952.45-10.2

certainty

type: Overall certainty

rating: High certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencyNOTSET
*IndirectnessNOTSET
*ImprecisionNOTSET
*Publication BiasNOTSET

Source1

{
  "resourceType": "Evidence",
  "id": "236978",
  "meta": {
    "versionId": "70",
    "lastUpdated": "2025-10-07T17:12:54.639Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://fevir.net/resources/Evidence/236978",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "236978",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "outcomeId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "313964"
    },
    {
      "type": {
        "text": "picoId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "85798"
    },
    {
      "type": {
        "text": "sectionId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "73215"
    }
  ],
  "name": "Genital_infection_from_MAGICapp_313964",
  "title": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
  "citeAs": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236978. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236978. Computable resource at: https://fevir.net/resources/Evidence/236978#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "ComparativeEvidence",
            "display": "ComparativeEvidence"
          }
        ]
      }
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo": [
    {
      "type": "part-of",
      "targetReference": {
        "type": "Composition",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "assertion": "SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.",
  "variableDefinition": [
    {
      "description": "Adults with type 2 diabetes",
      "variableRole": "population",
      "observed": {
        "reference": "Group/236947",
        "type": "Group",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Adults with type 2 diabetes and CVD and CKD"
      }
    },
    {
      "description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
      "variableRole": "exposure",
      "comparatorCategory": "GLP-1 RA",
      "observed": {
        "reference": "EvidenceVariable/236950",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
      }
    },
    {
      "description": "Genital infection",
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/236977",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-313964",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Genital infection"
      }
    }
  ],
  "synthesisType": [
    {
      "text": "SYSTEMATIC_REVIEW"
    }
  ],
  "studyDesign": [
    {
      "coding": [
        {
          "system": "http://hl7.org/fhir/study-design",
          "code": "SEVCO:01003",
          "display": "randomized assignment"
        }
      ]
    }
  ],
  "statistic": [
    {
      "description": "Risk Difference 15.8% (CI95 6.4% to 29.9%)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000424",
            "display": "risk difference"
          }
        ]
      },
      "quantity": {
        "value": 0.158
      },
      "sampleSize": {
        "numberOfStudies": 2,
        "numberOfParticipants": 1282
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": 0.064
            },
            "high": {
              "value": 0.299
            }
          }
        }
      ]
    },
    {
      "description": "OR 5.0 (CI95 2.45 to 10.2)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000182",
            "display": "odds ratio"
          }
        ]
      },
      "quantity": {
        "value": 5
      },
      "sampleSize": {
        "numberOfStudies": 2,
        "numberOfParticipants": 1282
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": 2.45
            },
            "high": {
              "value": 10.2
            }
          }
        }
      ]
    }
  ],
  "certainty": [
    {
      "type": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/certainty-type",
            "code": "Overall",
            "display": "Overall certainty"
          }
        ]
      },
      "rating": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/27834",
            "code": "RJCS-2003",
            "display": "High certainty"
          }
        ]
      },
      "subcomponent": [
        {
          "type": {
            "text": "Risk of Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Inconsistency"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Indirectness"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Imprecision"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Publication Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        }
      ]
    }
  ]
}